Milano & Partners’ Post

🔬 Big News for Biotech Innovators! 🌱 📅 Mark your calendars for Bio€quity Europe, Europe's premier congress for biotech investors and CEOs, coming to San Sebastian from May 12th to May 14th, 2024! 🚀 Organized by Grupo EBD Group and chaired by Spanish venture capital fund Ysios Capital, this year's event promises unparalleled networking opportunities and insightful discussions on the future of biotech. 2️⃣ For over two decades, Bio€quity Europe has been the go-to platform for industry leaders to forge partnerships, explore new ventures, and tackle key challenges shaping the biotech landscape. 🤝 Expect to connect with top-tier companies, specialized investors, and like-minded professionals eager to capitalize on emerging opportunities and foster synergies through strategic partnerships. 📢 Excitingly, ICEX Invest in Spain, alongside AseBio - Asociación Española de Bioempresas, will sponsor this edition, underscoring Spain's commitment to fostering innovation in the biotech sector. Join us as Alberto Sanz, Director of Financing and Investor Relations at ICEX, takes the stage on May 12th to showcase the myriad opportunities awaiting in the Spanish biotech landscape. 💼Seize this opportunity to immerse yourself in the forefront of biotech innovation and collaboration. See you at Bio€quity Europe 2024! https://lnkd.in/gH_eBNuW #BioequityEurope #BiotechInnovation #InvestInSpain #NetworkingOpportunities

Curious about how early-stage life science programs transform into successful ventures? Our Venture Developer & Lead Biotech, Lydia Kalafateli, recently shared with BIOstock how NLC drives health innovation by creating and investing in companies originating from early-stage life science projects and actively supporting their journey from founding to exit. If you’re attending BioEurope in Sweden, seize the opportunity to connect with Lydia in person! Discover firsthand how NLC is shaping the future of health innovation and empowering the next wave of groundbreaking ventures. #BIOEurope2024 #biotech #innovation #healthcare #impactinvesting

Attending #Bio Europe Spring again after some years has been inspiring. As former executive of a #Biotech company who now works as consultant for such companies, I enjoy learning about how much the Biotech environment has changed in #Europe and especially in #Spain. Six Spanish #Venturecapital entities organizing a joint together between companies and investors in globally is something that was a dream when I joined the sector in 2008. All of them are to be mentioned: Caixa Capital Risc, Asabys Partners, Invivo Partners, Ysios Capital, COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. and Aliath Bioventures I had the possibility to listen to many intriguing presentations from a wide range of perspectives: my friend Jose Mesa from COLUMBUS VENTURE PARTNERS,Sc.G.E.I.C., S.A.U. talked about their social view translated into the Fundación Columbus for treating children with #rarediseases. Clara Campàs Moya from Asabys Partners explained their investment strategy and how the impact of investments are measured from an #ESG perspective. Laura A. Lane from Eli Lilly and Company provided colour on their three-pilar strategy for investment and Alain Huriez Hureiz from AdBio partners gave his view as a foreign #VentureCapital investing in Spain. Lubor Gaal and Philippe Lopes-Fernandes gave concise advice, stating “Do not do it because of fashion” or “If you want to codevelop with pharma companies, have clear goals for such a cooperation or you will fail.” What does the future of #Biotech hold? I don’t know, but I leave this conference with new ideas and a sense of excitement for what is to come. 

#SwissBiotechDay Day 1 was impressive! The amount of meetings, panels, pitches is incredible. Some of my key takeaways would probably be: 👉 The Exit possibilities for longevity companies is huge - not only can you exit through pharma but also through nutrition, cosmetics, data and more (see picture on the top right) 👉 80% of the revenue in the European market comes from the top5 countries. 👉 The investor's money is there but they wait for the interests to drop in the US 👉 The IPO window might be open now but should close the nearer we get to the presidential election in the US. 👉 Swiss Biotech Startups are on top of their game and raising money! The Biotech CEO/investors networking apéro was just amazing and I am looking forward to support as many #Biotech companies as possible in their fundraising and exits. Let's see what day 2 will bring. Hit me up when you see me. #SwissMA

📊 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐁𝐢𝐨𝐄𝐮𝐫𝐨𝐩𝐞: 𝐓𝐡𝐞 𝐒𝐡𝐢𝐟𝐭𝐢𝐧𝐠 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 Today at BioEurope, new data reveals interesting changes in the biotech fundraising market. While the number of investment rounds is decreasing, the size of each round has grown significantly—reflecting a trend towards fewer but larger funding events. However, a notable funding gap remains between the U.S. and Europe, with U.S. investments almost double in size on average compared to those in Europe. This difference underlines both the challenge and the potential for European biotech to attract larger rounds and bolster innovation in the region. As we continue to navigate this changing landscape, how can we bridge this gap and foster growth within the European biotech ecosystem? Let's keep the conversation going on ways to drive global competitiveness and support biotech breakthroughs across borders. #BioEurope #Biotech #Fundraising #Investment #Innovation #LifeSciences #EuropeBiotech #FundingGaps

Join our panel Discussion at the #SwissBiotechDay to learn more about how we build and foster pioneering partnerships

T-minus 6 days and counting! 🚀 Looking forward to gaining insights on fostering strategic alliances at #SwissBiotechDay! Join the panel discussion to explore how innovative partnerships drive biotech forward. @SwissBiotechAssociation #IworkforCSL #SwissBiotechDay #BiotechInnovation #StrategicPartnerships

Three experts provide valuable insights into how founders can deal with an apparent paradox: building a competent team for the demanding tasks of a biotech start-up, while at the same time financing the company is becoming increasingly difficult. Many thanks to Helena Strigård for the succinct statements. https://lnkd.in/dzXGuzBz #biotech #constares #HaegerCarlsson

💼 EIS Investor Panel: Tips for Attracting Venture Capital in Retinal Innovation During the EURETINA Innovation Spotlight (EIS), venture capital experts shared valuable insights for retina specialists and researchers seeking funding for their innovative ideas. Representatives from SOFINNOVA PARTNERS, BIOGENERATION VENTURES, and MONOGRAPH BIO discussed the evolution of investment in retinal treatments over the past decade and what investors are looking for today. Here are some key takeaways: 💡 Lower-risk innovations are increasingly attractive, such as improving drug delivery and duration. 📈 Excite investors with science—investors are drawn to the full picture, from development potential to market size. 💪 Demonstrate clear advantages—ensure your innovation has an easy-to-prove, significant benefit. 🤝 Choose your partners wisely—investor relationships are partnerships, so align your goals. 🔗 Read the full article on the Euretina Congress Daily website: https://ow.ly/I5Xq50TKsVh #EURETINA24 #RetinaCare #VentureCapital #InvestmentTips #InnovationInOphthalmology #EIS2024

📣 Nordic Biotech Brilliance: Unleashing the Talent Magnet for Sustained and Retained Innovation Join our panel of Biotech Leaders as they discuss: ·  The importance of fostering collaboration between industry, academia, and research institutions to create a robust ecosystem that attracts talent. How can partnerships drive innovation and create a talent magnet for the Nordic region? ·  Strategies employed by companies to invest in talent development, training, and upskilling programs ·  How can Nordic companies create environments that prioritize the holistic needs of their workforce, ultimately fostering loyalty and satisfaction? ·  The impact of diversity and inclusion initiatives on attracting a diverse pool of talent 🎙 Hear from: · Mario Alzamora, Leader, Nucleate Denmark · Reagan Jarvis, CEO & Co-Founder, Anocca · Georgina Askeland, PhD, Principal, Hadean Ventures · Stine Kruse, Head of Startup Support and Business Development, DTU Find out more: https://lnkd.in/eD9En8fD #LSXNordic #Biotech